John D Hainsworth1, James A Reeves2, Joseph R Mace3, Edward J Crane4, Oday Hamid5, John R Stille5, Amy Flynt6, Stephanie Roberson5, John Polzer5, Edward R Arrowsmith7. 1. Sarah Cannon Research Institute/Tennessee Oncology, PLLC, 250 25th Ave N #100, Nashville, TN, 37203, USA. John.Hainsworth@scresearch.net. 2. Florida Cancer Specialists, Fort Myers, FL, USA. 3. Florida Cancer Specialists, St. Petersburg, FL, USA. 4. Oncology Hematology Care, Cincinnati, OH, USA. 5. Eli Lilly and Company, Indianapolis, IN, USA. 6. PharPoint Research Inc, Durham, NC, USA. 7. Tennessee Oncology, Chattanooga, TN, USA.
Abstract
PURPOSE: The chemokine (C-X-C Motif) receptor 4 (CXCR4) and its ligand, stromal-cell derived factor-1 (SDF-1), are frequently overexpressed in a variety of solid tumors, and are believed to play important roles in the regulation of organ-specific metastasis, tumor growth, invasion, and survival. In this randomized Phase 2 trial, we evaluated the safety and efficacy of LY2510924 (LY), a peptide antagonist of CXCR4, combined with sunitinib (SUN) in the first-line treatment of advanced renal cell carcinoma (RCC). PATIENTS AND METHODS: Eligible patients were randomized (2:1) to receive LY (20 mg SC daily) + SUN (50 mg PO daily for 4 weeks followed by 2 weeks off) or SUN alone. Response was assessed after two cycles; patients continued treatment until tumor progression or intolerable toxicity. The study was powered to detect a 47 % increase in median progression-free survival (PFS). RESULTS:One hundred eight patients were randomized and treated (LY + SUN, 72; SUN, 36); median duration of treatment of five cycles. Observed median PFS was 8.1 months with LY + SUN and 12.3 months with SUN; Bayesian time-to-event HR 1.23; 95 % credible interval: 0.74, 1.96. LY was well tolerated; the toxicity profile was typical of SUN. No efficacy differences were seen between treatments groups when subsets with high versus low levels of CXCR4 tumor expression were compared. CONCLUSIONS: The addition of LY to SUN in the first-line treatment of metastatic RCC was well tolerated, but did not improve the PFS or overall survival (OS) vs. SUN alone. CXCR4 remains an unproven therapeutic target for the treatment of RCC. GOV IDENTIFIER: NCT01391130.
RCT Entities:
PURPOSE: The chemokine (C-X-C Motif) receptor 4 (CXCR4) and its ligand, stromal-cell derived factor-1 (SDF-1), are frequently overexpressed in a variety of solid tumors, and are believed to play important roles in the regulation of organ-specific metastasis, tumor growth, invasion, and survival. In this randomized Phase 2 trial, we evaluated the safety and efficacy of LY2510924 (LY), a peptide antagonist of CXCR4, combined with sunitinib (SUN) in the first-line treatment of advanced renal cell carcinoma (RCC). PATIENTS AND METHODS: Eligible patients were randomized (2:1) to receive LY (20 mg SC daily) + SUN (50 mg PO daily for 4 weeks followed by 2 weeks off) or SUN alone. Response was assessed after two cycles; patients continued treatment until tumor progression or intolerable toxicity. The study was powered to detect a 47 % increase in median progression-free survival (PFS). RESULTS: One hundred eight patients were randomized and treated (LY + SUN, 72; SUN, 36); median duration of treatment of five cycles. Observed median PFS was 8.1 months with LY + SUN and 12.3 months with SUN; Bayesian time-to-event HR 1.23; 95 % credible interval: 0.74, 1.96. LY was well tolerated; the toxicity profile was typical of SUN. No efficacy differences were seen between treatments groups when subsets with high versus low levels of CXCR4tumor expression were compared. CONCLUSIONS: The addition of LY to SUN in the first-line treatment of metastatic RCC was well tolerated, but did not improve the PFS or overall survival (OS) vs. SUN alone. CXCR4 remains an unproven therapeutic target for the treatment of RCC. GOV IDENTIFIER: NCT01391130.
Authors: Natalie M Wilson; Hosung Jung; Matthew S Ripsch; Richard J Miller; Fletcher A White Journal: Brain Behav Immun Date: 2010-12-28 Impact factor: 7.217
Authors: Geoffrey L Uy; Michael P Rettig; Ibraheem H Motabi; Kyle McFarland; Kathryn M Trinkaus; Lindsay M Hladnik; Shashikant Kulkarni; Camille N Abboud; Amanda F Cashen; Keith E Stockerl-Goldstein; Ravi Vij; Peter Westervelt; John F DiPersio Journal: Blood Date: 2012-02-02 Impact factor: 22.113
Authors: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: Robert J Motzer; Brian I Rini; David F McDermott; Bruce G Redman; Timothy M Kuzel; Michael R Harrison; Ulka N Vaishampayan; Harry A Drabkin; Saby George; Theodore F Logan; Kim A Margolin; Elizabeth R Plimack; Alexandre M Lambert; Ian M Waxman; Hans J Hammers Journal: J Clin Oncol Date: 2014-12-01 Impact factor: 44.544
Authors: Zhongxing Liang; Younghyoun Yoon; John Votaw; Mark M Goodman; Larry Williams; Hyunsuk Shim Journal: Cancer Res Date: 2005-02-01 Impact factor: 12.701
Authors: Rose Du; Kan V Lu; Claudia Petritsch; Patty Liu; Ruth Ganss; Emmanuelle Passegué; Hanqiu Song; Scott Vandenberg; Randall S Johnson; Zena Werb; Gabriele Bergers Journal: Cancer Cell Date: 2008-03 Impact factor: 31.743
Authors: Ilya V Ulasov; Anton V Borovjagin; Peter Timashev; Massimo Cristofanili; Danny R Welch Journal: Cancer Metastasis Rev Date: 2019-09 Impact factor: 9.264
Authors: Fabian Hofmann; Eu Chang Hwang; Thomas Bl Lam; Axel Bex; Yuhong Yuan; Lorenzo So Marconi; Börje Ljungberg Journal: Cochrane Database Syst Rev Date: 2020-10-14